Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.80 |
| ▸ | LMNA | P02545 | 3/20 | 0.80 |
| ▸ | POLB | P06746 | 2/20 | 0.62 |
| ▸ | CDC25A | P30304 | 1/20 | 0.60 |
| ▸ | USP2 | O75604 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.59 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.58 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.58 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.58 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.58 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.57 |
| ▸ | HTR6 | P50406 | 1/20 | 0.57 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.57 |
| ▸ | PLK1 | P53350 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7698481 | 0.91 | LMNA (0.77) | ALDH1A1LMNAPOLBCDC25AUSP2 | |
| SCHEMBL1233547 | 0.90 | ALDH1A1 (0.67) | ALDH1A1LMNAPOLBCDC25AHDAC1 | |
| SCHEMBL4548571 | 0.90 | ALDH1A1 (0.67) | ALDH1A1LMNAPOLBCDC25AUSP2 | |
| SCHEMBL27794777 | 0.90 | LMNA (0.67) | ALDH1A1LMNAPOLBUSP2HSD17B10 | |
| SCHEMBL6893171 | 0.89 | LMNA (1.00) | ALDH1A1LMNAPOLBCDC25AUSP2 | |
| SCHEMBL8289938 | 0.88 | PLA2G2A (0.74) | ALDH1A1LMNAPOLBPLA2G2ASMN1; SMN2 | |
| SCHEMBL13931026 | 0.88 | ALDH1A1 (0.65) | ALDH1A1LMNAPOLBCDC25AHDAC1 | |
| SCHEMBL13930959 | 0.87 | LMNA (0.74) | ALDH1A1LMNACDC25ACHRNB2CHRNA7 | |
| SCHEMBL4262388 | 0.87 | ALDH1A1 (0.67) | ALDH1A1LMNAPOLBCDC25AUSP2 | |
| SCHEMBL7692305 | 0.87 | CHRM1 (0.65) | ALDH1A1LMNAPOLBCDC25AHDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1146905-A1 | COX-2 INHIBITORS IN COMBINATION WITH NMDA-BLOCKERS FOR TREATING PAIN | Algos Pharmaceutical Corporation (US) | 2001-10-24 | — | — | EP | claimed |
| WO-2000029022-A1 | COX-2 INHIBITORS IN COMBINATION WITH CENTRALLY ACTING ANALGESICS | ALGOS PHARMACEUTICAL CORPORATION (US) | 2000-05-25 | — | — | WO | claimed |
| WO-2000029023-A1 | COX-2 INHIBITORS IN COMBINATION WITH NMDA-BLOCKERS FOR TREATING PAIN | ALGOS PHARMACEUTICAL CORPORATION (US) | 2000-05-25 | — | — | WO | claimed |
| WO-1998050075-A1 | COX-2 INHIBITORS IN COMBINATION WITH NMDA-BLOCKERS FOR TREATING PAIN | ALGOS PHARMACEUTICAL CORPORATION (US) | 1998-11-12 | — | — | WO | claimed |
| US-7964738-B2 | Pharmaceutical compositions and methods of use of lipophilic, silicon-substituted, cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs and derivatives | SILAMED, INC. (US) | 2011-06-21 | — | — | US | disclosed |
| WO-2010083501-A2 | ALPHA-HELIX MIMETIC USING A 2,5-OLIGOPYRIMIDINE SCAFFOLD | UNIVERSITY OF SOUTH FLORIDA (US) | 2010-07-22 | — | — | WO | disclosed |
| EP-2101736-A2 | HOMOGENEOUS PASTE AND GEL FORMULATIONS | Merial Limited (US) | 2009-09-23 | — | — | EP | disclosed |
| CN-100420672-C | Selective COX-2 inhibitory novel esters from indolealkanols and novel amides from indolealkylamines | UNIV VANDERBILT (US) | 2008-09-24 | — | — | CN | disclosed |
| WO-2008077130-A2 | HOMOGENEOUS PASTE AND GEL FORMULATIONS | MERIAL LIMITED (US) | 2008-06-26 | — | — | WO | disclosed |
| US-20080027011-A1 | Homogeneous paste and gel formulations | MERIAL LIMITED | 2008-01-31 | — | — | US | disclosed |
| EP-1225882-B1 | SELECTIVE COX-2 INHIBITORY NOVEL ESTERS FROM INDOLEALKANOLS AND NOVEL AMIDES FROM INDOLEALKYLAMINES | UNIV VANDERBILT (US) | 2007-10-17 | — | — | EP | disclosed |
| US-20070129331-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF LIPOPHILIC, SILICON-SUBSTITUTED, CYCLOOXYGENASE-2 SELECTIVE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND DERIVATIVES | RND PHARMACEUTICALS, INC. (US) | 2007-06-07 | — | — | US | disclosed |
| WO-1998050075-A1 | COX-2 INHIBITORS IN COMBINATION WITH NMDA-BLOCKERS FOR TREATING PAIN | ALGOS PHARMACEUTICAL CORPORATION (US) | 1998-11-12 | — | — | WO | disclosed |
| EP-0746544-B1 | NOVEL INDOLE DERIVATIVES USEFUL TO TREAT ESTROGEN-RELATED NEOPLASMS AND DISORDERS | MERRELL PHARMA INC (US) | 1998-09-09 | — | — | EP | disclosed |
| WO-1997019911-A1 | AMINO ACID DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS AND PROCESSES FOR PREPARING THEM | DR. KARL THOMAE GMBH (DE) | 1997-06-05 | — | — | WO | disclosed |
| CN-1141627-A | Indole derivatives for the treatment of estrogen-related tumors and diseases | MERRELL DOW PHARMA (US) | 1997-01-29 | — | — | CN | disclosed |
| EP-0746544-A1 | NOVEL INDOLE DERIVATIVES USEFUL TO TREAT ESTROGEN-RELATED NEOPLASMS AND DISORDERS | MERRELL PHARMACEUTICALS INC. (US) | 1996-12-11 | — | — | EP | disclosed |
| US-5510368-A | INHIBITORS OF CYCLOOXYGENASE | MERCK FROSST CANADA, INC. (CA) | 1996-04-23 | — | — | US | disclosed |
| WO-1996003377-A1 | HETEROCYCLIC COMPOUNDS, USEFUL AS ALLOSTERIC EFFECTORS AT MUSCARINIC RECEPTORS | SANKYO COMPANY, LIMITED (JP) | 1996-02-08 | — | — | WO | disclosed |
| WO-1995022524-A1 | NOVEL INDOLE DERIVATIVES USEFUL TO TREAT ESTROGEN-RELATED NEOPLASMS AND DISORDERS | MERRELL PHARMACEUTICALS INC. (US) | 1995-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027011-A1 | Homogeneous paste and gel formulations | EPX, CAT, PEF1 | ALDH1A1 1981/4885LMNA 1258/4885POLB 940/4885 |
| US-20070129331-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF LIPOPHILIC, SILICON-SUBSTITUTED, CYCLOOXYGENASE-2 SELECTIVE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND DERIVATIVES | PTGES2, PTGS2, SI | ALDH1A1 2639/4885LMNA 3383/4885POLB 2634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.